Xeris Biopharma (XERS) News Today $4.56 +0.02 (+0.46%) As of 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XERS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term InvestingJune 18 at 10:17 AM | seekingalpha.comXeris Biopharma (NASDAQ:XERS) Stock Price Up 8.4% Following Insider Buying ActivityJune 18 at 1:11 AM | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Trading Up 8.4% on Insider Buying ActivityXeris Biopharma (NASDAQ:XERS) Shares Up 8.4% on Insider Buying ActivityJune 17 at 10:18 AM | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 SharesJune 17 at 4:49 AM | insidertrades.comKevin Mcculloch Purchases 25,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) StockXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Kevin Mcculloch acquired 25,000 shares of Xeris Biopharma stock in a transaction on Friday, June 13th. The shares were purchased at an average cost of $4.38 per share, with a total value of $109,500.00. Following the completion of the acquisition, the insider now owns 1,708,585 shares of the company's stock, valued at $7,483,602.30. This trade represents a 1.48% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.June 16 at 6:19 PM | marketbeat.comLeerink Partnrs Estimates Xeris Biopharma FY2025 EarningsXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities researchers at Leerink Partnrs issued their FY2025 earnings estimates for Xeris Biopharma in a report released on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz expects that the company will post earnings per share of ($0June 9, 2025 | marketbeat.comQ3 EPS Estimates for Xeris Biopharma Cut by Leerink PartnrsJune 8, 2025 | americanbankingnews.comLeerink Partnrs Cuts Earnings Estimates for Xeris BiopharmaXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q3 2025 earnings per share estimates for Xeris Biopharma in a research note issued on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will pJune 6, 2025 | marketbeat.comMackenzie Financial Corp Buys 106,153 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Mackenzie Financial Corp raised its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 446.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 129,952 shares of the company's stock after acquiring an additionalJune 4, 2025 | marketbeat.comXeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor DayJune 3, 2025 | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Shares Down 5.5% - Here's What HappenedXeris Biopharma (NASDAQ:XERS) Trading Down 5.5% - Here's What HappenedJune 3, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from AnalystsShares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rJune 3, 2025 | marketbeat.comNuveen Asset Management LLC Acquires 228,380 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Nuveen Asset Management LLC boosted its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 13.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,903,442 shares of the company's stJune 1, 2025 | marketbeat.comMillennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Millennium Management LLC increased its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 34.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,948,552 shares of the company's stock after acquMay 29, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)BNP Paribas Financial Markets bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 100,012 shares of the company's stock, valued at approximately $339,000. BNPMay 28, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Rating Lowered to Hold at Wall Street ZenWall Street Zen lowered Xeris Biopharma from a "buy" rating to a "hold" rating in a report on Thursday.May 24, 2025 | marketbeat.comXeris Announces Details for Analyst & Investor DayMay 20, 2025 | businesswire.comStonepine Capital Management LLC Makes New $618,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Stonepine Capital Management LLC bought a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 182,317 shares of the company's stock, valued at apMay 20, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by D. E. Shaw & Co. Inc.D. E. Shaw & Co. Inc. grew its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 38.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,363,452 shares of the company's stock after buying an adMay 20, 2025 | marketbeat.comLeerink Partnrs Weighs in on Xeris Biopharma Q2 EarningsXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Xeris Biopharma in a note issued to investors on Monday, May 12th. Leerink Partnrs analyst R. Ruiz forecasts that the company will earn ($0.01)May 17, 2025 | marketbeat.comParkman Healthcare Partners LLC Increases Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Parkman Healthcare Partners LLC raised its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 465.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 578,511 shares of the company's stockMay 16, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Lowers Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Schonfeld Strategic Advisors LLC reduced its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 40.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,000 shares of thMay 13, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in NowMay 12, 2025 | msn.comDriehaus Capital Management LLC Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Driehaus Capital Management LLC bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 594,015 shares of the company's stock, valuedMay 12, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comXeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...May 9, 2025 | finance.yahoo.comTudor Investment Corp ET AL Reduces Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Tudor Investment Corp ET AL cut its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 39.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 305,186 shares of the company's stock after selling 202,171 shares during thMay 9, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comXeris Biopharma Reports Record First Quarter 2025 Financial ResultsMay 8, 2025 | businesswire.com4XERS : Earnings Outlook For Xeris Biopharma HoldingsMay 7, 2025 | benzinga.comXeris Biopharma Holdings: Looking For More Growth In Q1 EarningsMay 7, 2025 | seekingalpha.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Position Reduced by Caxton CorpCaxton Corp cut its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 60.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,015,157 shares of the company's stock aftMay 7, 2025 | marketbeat.comXeris Biopharma (XERS) Projected to Post Earnings on ThursdayXeris Biopharma (NASDAQ:XERS) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-xeris-pharmaceuticals-inc-stock/)May 3, 2025 | marketbeat.comXeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025May 2, 2025 | seekingalpha.comXeris Biopharma (NASDAQ:XERS) Sees Large Volume Increase - Time to Buy?Xeris Biopharma (NASDAQ:XERS) Sees Unusually-High Trading Volume - What's Next?April 30, 2025 | marketbeat.comXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To ProfitApril 26, 2025 | finance.yahoo.comIs Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires?April 23, 2025 | msn.comJPMorgan Chase & Co. Has $3.54 Million Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)JPMorgan Chase & Co. increased its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 166.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,043,441 shares of tApril 22, 2025 | marketbeat.comRenaissance Technologies LLC Raises Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Renaissance Technologies LLC grew its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 31.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,098,840 shares of the company's stock after buying an additional 500,120 shares duringApril 21, 2025 | marketbeat.comEAM Investors LLC Buys New Shares in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)EAM Investors LLC purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 222,377 shares of the company's stock, valApril 20, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Trading Down 4.9% - Here's What HappenedXeris Biopharma (NASDAQ:XERS) Stock Price Down 4.9% - Time to Sell?April 18, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Large Growth in Short InterestXeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 17,040,000 shares, an increase of 52.0% from the March 15th total of 11,210,000 shares. Based on an average daily trading volume, of 2,810,000 shares, the days-to-cover ratio is currently 6.1 days. Currently, 12.0% of the shares of the stock are sold short.April 18, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Shares Up 4.9% - What's Next?Xeris Biopharma (NASDAQ:XERS) Stock Price Up 4.9% - Here's What HappenedApril 17, 2025 | marketbeat.comKennedy Capital Management LLC Boosts Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)Kennedy Capital Management LLC boosted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 10.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 666,095 shares of theApril 16, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Vanguard Group Inc.Vanguard Group Inc. increased its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 1.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,899,063 shares of the company's stock after purchasing an additional 1April 16, 2025 | marketbeat.comCenterBook Partners LP Sells 2,791,929 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)CenterBook Partners LP reduced its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 80.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 690,077 shares of the company's stock after selling 2,791,929 shares during the period. CenterBookApril 12, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Trading Down 6.2% - Here's WhyXeris Biopharma (NASDAQ:XERS) Shares Down 6.2% - Should You Sell?April 3, 2025 | marketbeat.comAIGH Capital Management LLC Acquires 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)AIGH Capital Management LLC raised its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 17.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,574,846 shares of the company's stock aftMarch 31, 2025 | marketbeat.comXeris Announces Changes to Its Board of DirectorsMarch 28, 2025 | finance.yahoo.comIs Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?March 27, 2025 | msn.com Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address XERS Media Mentions By Week XERS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XERS News Sentiment▼1.300.56▲Average Medical News Sentiment XERS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XERS Articles This Week▼62▲XERS Articles Average Week Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MLTX News OGN News IMVT News MIRM News XENE News AMRX News APLS News NAMS News BHC News ARWR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XERS) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredElon’s End Game Is Going Live -- And It Could Make You a FortuneThe media and the so-called experts have laughed at Elon Musk his entire career. CBS called PayPal “one of ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredThe Dollar Reset Nobody’s Talking AboutCould this man take down the financial system? In March, the Senate granted sweeping powers to a Harvard ec...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XERS Stock Free XERS Stock Alerts